Speak with one of our advisors: 0800 085 6663 or

Prof. Gordon. C. Wishart

Prof Gordon Wishart

Professor Gordon Wishart graduated MB ChB from the University of Edinburgh in 1983 followed by an MD in 1992 for a thesis entitled "Aspects of multidrug resistance in breast cancer". Professor Wishart received fellowships from the Royal College of Physicians and Surgeons of Glasgow in 1987 and the Royal College of Surgeons of England in 2001. Following his first consultant appointment in Sussex in 1995, Professor GC Wishart moved to Addenbrooke's Hospital, Cambridge in 1998 to take up the post of consultant breast & endocrine surgeon with a remit to develop and modernise breast cancer services. Professor Gordon C Wishart was Director of the Cambridge Breast Unit from 2005 to 2010 and was appointed as Visiting Professor of Cancer Surgery at Anglia Ruskin University, Cambridge in December 2008.

Professor Wishart has a national and international reputation in the field of breast cancer and has published widely in the field of breast cancer, including sentinel node biopsy, endocrine surgery and breast cancer. A full list of his publications is listed below and can also be found on the PubMed website by searching for Wishart GC. In some of his research articles he will be listed as GC Wishart. Professor Gordon Wishart was instrumental in raising £2 million to build the Cambridge Breast Cancer Research Unit in 2008, a clinical and laboratory facility to support the clinical research programme. He is the lead or co-investigator on clinical trials that have attracted over £2 million in grant funding. He has recently been an advisor to the Department of Health as part of the cancer waiting times and national cancer survivorship initiatives.

Professor Wishart's main areas of research interest include factors that lead to variation in breast cancer survival and the effect of screen-detection on survival. He recently led a team of clinicians and scientists to produce a new model, Predict, that estimates the survival and treatment benefits following surgery for invasive breast cancer (www.predict.nhs.uk). The second version of Predict, launched in July 2011, is the first clinical prognostication model for breast cancer to include HER2 and the benefit of trastuzumab (Herceptin).

With many years of clinical experience, and an active research interest in the prediction of breast cancer survival, Professor Gordon Wishart is in an ideal position to provide expert witness medical reports on cases of clinical negligence related to breast cancer diagnosis and treatment, especially delay in diagnosis.

© 2020 Check4Cancer, Lower Court 3-4, Copley Hill Business Park, Cambridge Road, Cambridge, CB22 3GN
Registered in England and Wales. Company registration number 08866941